Davita Inc vs Vistra Corp — how do they compare? Davita Inc trades at $179.25 (market cap $11.29B), while Vistra Corp trades at $161.48 (market cap $52.41B). The key difference: Vistra Corp is far larger — about 4.6× Davita Inc's market cap, and Vistra Corp pays a 0.59% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Vistra Corp for 32 Days on average.
| DVA | VST | |
|---|---|---|
Market Cap | $11.29B | $52.41B |
Volume | 582,204 | 11,278,074 |
Sector | Health | Utilities |
52-Week High | $240.96 | $210.85 |
52-Week Low | $103.87 | $134.71 |
Typical Hold Time | 114 Days | 32 Days |
Enterprise Value | $24.01B | $74.34B |
Dividend Yield | — | 0.59% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.
Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.
Vistra Corp. (VST) trades at $161.48, down 3.14% on the day, amid mixed earnings history but strong analyst support. Technicals are bullish with support at $152 and resistance at $164, while fundamentals show robust profitability with an 11.55% net margin and 75.73% ROE. Recent developments include a $4.2 billion US loan for nuclear expansion and a 20-year power deal with New Era Energy, positioning Vistra to capitalize on AI-driven electricity demand.
The outlook is positive with a consensus price target of $215.23 implying 33% upside, driven by nuclear scale and data center partnerships. Risks include earnings volatility and high debt, but institutional bullishness and AI power scarcity trends offer a compelling growth narrative for investors seeking exposure to the energy transition.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →